Longenesis joins forces with Northern European oncologists‍

Longenesis joins forces with Northern European oncologists

‍

• A new model for breast cancer-related risk calculation was proposed by  DF LAB Healthcare Technology Project Laboratory (University of Latvia), VITA female oncology patient association.
• A tool will serve to educate and raise awareness about breast and cervical cancer-related risks, involve patients/users into virtual study and correlate multiple data types for risk assessment.

Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Bitfury Group founder is from Latvia, by the way.

Longenesis is a company disrupting an industry for compliant access to medical data for clinical studies, formed a partnership alliance together with DF LAB Healthcare Technology Project Laboratory (University of Latvia), VITA female oncology patient association to launch a digital breast and cervical cancer pre-screening program for early diagnostics and proactive involvement in cancer-related studies in Northern European region.

Partners propose a new model for breast cancer-related risk calculation. It is based on a web interface and involves multiple data types, such as phenotypic metrics (survey results), visual red flags (early breast cancer symptoms), self-examination tool and genotypic data (genotypic result upload form). The model is implemented in a web-based tool where users have the ability to proactively enter the data into the platform and receive a customized report + “how-to” instructions for performing a standard screening in the Baltic region and receiving subsidized ancestor mutations genotypic testing.

‍

Read the full article at Labs of Latvia